Enanta Pharmaceuticals (ENTA) Retained Earnings (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Retained Earnings of -$430.0 million for Q1 2026, down 16.84% year-on-year from -$517.1 million in Q1 2025, and down 130586.32% on a QoQ basis from -$329000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Retained Earnings data on file, last reported at -$430.0 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 16.84% year-over-year to -$430.0 million; the trailing twelve-month figure through Mar 2026 stood at -$430.0 million (down 16.84% YoY), and the FY2025 full-year result was -$339000.0, up 99.9% from the prior year.
- Retained Earnings for Q1 2026 stood at -$430.0 million, down from -$329000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at -$329000.0 in Q4 2025 and bottomed at -$430.0 million in Q1 2026.
- The 5-year median for Retained Earnings is -$46.8 million (2022), against an average of -$131.1 million.
- The widest annual swing landed in 2024, when Retained Earnings plunged 64568.54%; it then soared 99.9% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$102.2 million in 2022, then soared by 99.48% to -$534000.0 in 2023, then slumped by 64568.54% to -$345.3 million in 2024, then jumped by 99.9% to -$329000.0 in 2025, then sank by 130586.32% to -$430.0 million in 2026.
- The last three Retained Earnings figures came in at -$430.0 million (Q1 2026), -$329000.0 (Q4 2025), and -$339000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -429.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -429.96 Mn |
| Dec 31, 2025 | -329,000.00 |
| Sep 30, 2025 | -339,000.00 |
| Jun 30, 2025 | -402,000.00 |
| Mar 31, 2025 | -367.97 Mn |
| Dec 31, 2024 | -345.33 Mn |
| Sep 30, 2024 | -323.04 Mn |
| Jun 30, 2024 | -653,000.00 |
| Mar 31, 2024 | -271.56 Mn |
| Dec 31, 2023 | -534,000.00 |
| Sep 30, 2023 | -1.17 Mn |
| Jun 30, 2023 | -178.89 Mn |
| Mar 31, 2023 | -139.82 Mn |
| Dec 31, 2022 | -102.17 Mn |
| Sep 30, 2022 | -3.72 Mn |
| Jun 30, 2022 | -46.83 Mn |
| Mar 31, 2022 | -15.13 Mn |
| Dec 31, 2021 | 18.46 Mn |
| Sep 30, 2021 | -382,000.00 |
| Jun 30, 2021 | -264,000.00 |
| Mar 31, 2021 | 55,000.00 |
| Dec 31, 2020 | 405,000.00 |
| Sep 30, 2020 | 127.57 Mn |
| Jun 30, 2020 | 1.46 Mn |
| Mar 31, 2020 | 608,000.00 |
| Dec 31, 2019 | 177.18 Mn |
| Sep 30, 2019 | 146,000.00 |
| Jun 30, 2019 | 163,000.00 |
| Mar 31, 2019 | -12,000.00 |
| Dec 31, 2018 | -257,000.00 |
| Sep 30, 2018 | 117.36 Mn |
| Jun 30, 2018 | -595,000.00 |
| Mar 31, 2018 | -794,000.00 |
| Dec 31, 2017 | 57.09 Mn |
| Sep 30, 2017 | 45.36 Mn |
| Jun 30, 2017 | 8.85 Mn |
| Mar 31, 2017 | 17.27 Mn |
| Dec 31, 2016 | 22.67 Mn |
| Sep 30, 2016 | 27.65 Mn |
| Jun 30, 2016 | 29.45 Mn |
| Mar 31, 2016 | 201,000.00 |
| Dec 31, 2015 | 32.17 Mn |
| Sep 30, 2015 | 5.98 Mn |
| Jun 30, 2015 | 168,000.00 |
| Mar 31, 2015 | -17,000.00 |
| Dec 31, 2014 | -31.00 Mn |
| Sep 30, 2014 | -100,000.00 |
| Jun 30, 2014 | -4,000.00 |
| Mar 31, 2014 | 61,000.00 |
| Dec 31, 2013 | -112.82 Mn |
| Sep 30, 2013 | -107.45 Mn |
| Jun 30, 2013 | -103.01 Mn |
| Mar 31, 2013 | -98.87 Mn |
| Sep 30, 2012 | 10,000.00 |